Marie-Eve Rouge-Bugat1,2,3, Donia Lassoued4, Joy Bacrie4, Nathalie Boussier4, Jean-Pierre Delord5, Stéphane Oustric4, Eric Bauvin6, Maryse Lapeyre-Mestre7, François Bertucci8, Pascale Grosclaude7,9. 1. Département Universitaire de Médecine Générale, 133 route de Narbonne, 31062, Toulouse, France. marieeve.rouge-bugat@dumg-toulouse.fr. 2. Faculté de Médecine, UMR 1027 INSERM-UPS, 37 Allées Jules Guesde, 31000, Toulouse, France. marieeve.rouge-bugat@dumg-toulouse.fr. 3. Institut Universitaire du Cancer IUCT-Oncopole, 1, avenue Irène Joliot-Curie, 31059, Toulouse, Cedex 9, France. marieeve.rouge-bugat@dumg-toulouse.fr. 4. Département Universitaire de Médecine Générale, 133 route de Narbonne, 31062, Toulouse, France. 5. Institut Universitaire du Cancer IUCT-Oncopole, 1, avenue Irène Joliot-Curie, 31059, Toulouse, Cedex 9, France. 6. Réseau Régional de Cancérologie Oncomip, IUCT-Oncopole, 1, avenue Irène Joliot-Curie, 31059, Toulouse, Cedex 9, France. 7. Faculté de Médecine, UMR 1027 INSERM-UPS, 37 Allées Jules Guesde, 31000, Toulouse, France. 8. Département d'Oncologie Médicale, Institut Paoli-Calmettes, 232, Boulevard de Sainte-Marguerite, 13009, Marseille, France. 9. Registre des Cancers du Tarn, BP37 81000, Albi, Cedex 01, France.
Abstract
PURPOSE: General practitioners (GPs) are more and more involved in the treatment of cancer patients but feel not informed enough about anticancer treatments and associated side effects. Better communication with treatment centers is needed. We hypothesized that information sheets could improve communication. METHODS: This prospective, multicentric, and interventionist study aimed at implementing and assessing therapeutic sheets describing the side effects of anticancer drugs used for digestive and gynecological cancers and their recommended management. GPs' phone interviews were done through three successive phases and two independent cohorts. The first phase (T1; 242 GPs with one patient recently treated) listed their expectations, the second (T2; 158 GPs with one patient beginning treatment) assessed the GPs' opinion regarding the sheets, and the third (T3; responder GPs 4 months after the start of T2) assessed their usefulness in practice. RESULTS: In T1, 94% of GPs declared their need of having information sheets, notably for the management of side effects. Thirty-one one-page sheets were created. In T2, 83.5% gave a favorable opinion about sheets and 80% envisaged their use in the case of side effect. In T3, 56% of GPs whose patient had experienced a side effect had used successfully the sheets for its management, and 21% of patients with side effect were hospitalized. A strong correlation existed between the use of the sheet by GPs and the hospitalization (OR 7.35 in the case of no use vs use). CONCLUSION: The guideline sheets represent a simple and low-cost solution to help GPs managing drugs' side effects and perhaps decrease the rate of unplanned hospitalizations.
PURPOSE: General practitioners (GPs) are more and more involved in the treatment of cancerpatients but feel not informed enough about anticancer treatments and associated side effects. Better communication with treatment centers is needed. We hypothesized that information sheets could improve communication. METHODS: This prospective, multicentric, and interventionist study aimed at implementing and assessing therapeutic sheets describing the side effects of anticancer drugs used for digestive and gynecological cancers and their recommended management. GPs' phone interviews were done through three successive phases and two independent cohorts. The first phase (T1; 242 GPs with one patient recently treated) listed their expectations, the second (T2; 158 GPs with one patient beginning treatment) assessed the GPs' opinion regarding the sheets, and the third (T3; responder GPs 4 months after the start of T2) assessed their usefulness in practice. RESULTS: In T1, 94% of GPs declared their need of having information sheets, notably for the management of side effects. Thirty-one one-page sheets were created. In T2, 83.5% gave a favorable opinion about sheets and 80% envisaged their use in the case of side effect. In T3, 56% of GPs whose patient had experienced a side effect had used successfully the sheets for its management, and 21% of patients with side effect were hospitalized. A strong correlation existed between the use of the sheet by GPs and the hospitalization (OR 7.35 in the case of no use vs use). CONCLUSION: The guideline sheets represent a simple and low-cost solution to help GPs managing drugs' side effects and perhaps decrease the rate of unplanned hospitalizations.
Entities:
Keywords:
Cancer treatment; Digestive cancer; General practice; Guidelines sheets; Gynecological cancer; Side effects
Authors: A Belot; P Grosclaude; N Bossard; E Jougla; E Benhamou; P Delafosse; A-V Guizard; F Molinié; A Danzon; S Bara; A-M Bouvier; B Trétarre; F Binder-Foucard; M Colonna; L Daubisse; G Hédelin; G Launoy; N Le Stang; M Maynadié; A Monnereau; X Troussard; J Faivre; A Collignon; I Janoray; P Arveux; A Buemi; N Raverdy; C Schvartz; M Bovet; L Chérié-Challine; J Estève; L Remontet; M Velten Journal: Rev Epidemiol Sante Publique Date: 2008-06-10 Impact factor: 1.019
Authors: Carriene Roorda; Geertruida H de Bock; Willem Jan van der Veen; Annemarie Lindeman; Liesbeth Jansen; Klaas van der Meer Journal: Support Care Cancer Date: 2011-03-25 Impact factor: 3.603